Asset Details
Do you wish to reserve the book?
Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis
Do you wish to request the book?
Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis
2020
Overview
Angiotensin-converting enzyme 2 (ACE2) is an endogenous counter-regulator of the renin–angiotensin hormonal cascade. We assessed whether plasma ACE2 concentrations were associated with greater risk of death or cardiovascular disease events.
We used data from the Prospective Urban Rural Epidemiology (PURE) prospective study to conduct a case-cohort analysis within a subset of PURE participants (from 14 countries across five continents: Africa, Asia, Europe, North America, and South America). We measured plasma concentrations of ACE2 and assessed potential determinants of plasma ACE2 levels as well as the association of ACE2 with cardiovascular events.
We included 10 753 PURE participants in our study. Increased concentration of plasma ACE2 was associated with increased risk of total deaths (hazard ratio [HR] 1·35 per 1 SD increase [95% CI 1·29–1·43]) with similar increases in cardiovascular and non-cardiovascular deaths. Plasma ACE2 concentration was also associated with higher risk of incident heart failure (HR 1·27 per 1 SD increase [1·10–1·46]), myocardial infarction (HR 1·23 per 1 SD increase [1·13–1·33]), stroke (HR 1·21 per 1 SD increase [1·10–1·32]) and diabetes (HR 1·44 per 1 SD increase [1·36–1·52]). These findings were independent of age, sex, ancestry, and traditional cardiac risk factors. With the exception of incident heart failure events, the independent relationship of ACE2 with the clinical endpoints, including death, remained robust after adjustment for BNP. The highest-ranked determinants of ACE2 concentrations were sex, geographic ancestry, and body-mass index (BMI). When compared with clinical risk factors (smoking, diabetes, blood pressure, lipids, and BMI), ACE2 was the highest ranked predictor of death, and superseded several risk factors as a predictor of heart failure, stroke, and myocardial infarction.
Increased plasma ACE2 concentration was associated with increased risk of major cardiovascular events in a global study.
Canadian Institute of Health Research, Heart & Stroke Foundation of Canada, and Bayer.
Publisher
Elsevier Ltd,Elsevier B.V,Elsevier Limited
Subject
/ Adult
/ Aged
/ Angiotensin-Converting Enzyme 2
/ Cardiovascular Diseases - blood
/ Cardiovascular Diseases - mortality
/ COVID-19
/ Death
/ Diabetes
/ Enzymes
/ Female
/ Genomes
/ Humans
/ Lipids
/ Male
/ Peptidyl-Dipeptidase A - blood
/ Plasma
/ Proteins
/ Rankings
/ Renin
/ Severe acute respiratory syndrome coronavirus 2
/ Sex
/ Stroke
